{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:14:17Z","timestamp":1789010057627,"version":"build-2803163510"},"reference-count":38,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pituitary neuroendocrine tumors (PitNETs) constitute a significant proportion of primary intracranial neoplasms and were historically differentiated based on clinical hormone excess syndromes and tinctorial properties. The 5th edition of the WHO classification introduces a paradigm shift towards the lineage-based taxonomy based on the cell-specific expression of transcription factors (TFs). This overview focuses on the biological justifications and diagnostic value of the core TFs of Pituitary-Specific Positive Transcription Factor 1 (PIT1), T-Box Pituitary Transcription Factor (TPIT), and Steroidogenic Factor 1 (SF1), which signify the somatotroph, lactotroph, thyrotroph, corticotroph, and gonadotroph lineages, respectively. By focusing on TF expressions instead of hormone immunoreactivity, pathologists can better subtype clinically non-functioning tumors, effectively relegating the previously overutilized null cell category to about 1% of cases. The TF-based classification is also essential in discriminating high-risk histotypes of silent corticotroph tumors, sparsely granulated somatotrophs, and immature PIT1-lineage PitNETs, which are linked to a higher invasiveness and recurrence. We suggest a practical, stepwise immunohistochemical diagnostic algorithm with the integration of ancillary markers (e.g., GATA3 and ER\u03b1) to refine lineage assignment. New molecular correlates such as GNAS and USP8 mutations also add to this framework and guide the use of individualized treatment involving somatostatin analogs or dopamine agonists. And lastly, we discuss the ongoing issues of diagnosis of triple-negative and multilineage tumors and the growing importance of DNA methylation profiling and artificial intelligence in standardized reporting and improving precision management.<\/jats:p>","DOI":"10.3390\/ijms27052307","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:39:56Z","timestamp":1772455196000},"page":"2307","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Transcription Factor\u2013Based Classification of Pituitary Neuroendocrine Tumors: Practical Immunohistochemical Algorithms, Molecular Correlates, and Diagnostic Challenges in the 5th WHO Era"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3513-9366","authenticated-orcid":false,"given":"Nirmal","family":"Pandit","sequence":"first","affiliation":[{"name":"Laboratory of Pathology, Department of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia 2408, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8628-6991","authenticated-orcid":false,"given":"Yahya","family":"Wehbeh","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Department of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia 2408, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8673-7104","authenticated-orcid":false,"given":"Omar","family":"Itani","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Department of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia 2408, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1428-8394","authenticated-orcid":false,"given":"Dimitrios","family":"Kanakis","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Department of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia 2408, Cyprus"},{"name":"Centre of Neuroscience and Integrative Brain Research (CENIBRE), University of Nicosia Medical School, Nicosia 2408, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41379-021-00820-y","article-title":"Pituitary neuroendocrine tumors: A model for neuroendocrine tumor classification","volume":"34","author":"Asa","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e13299","DOI":"10.1111\/bpa.13299","article-title":"Grading and staging for pituitary neuroendocrine tumors","volume":"35","author":"Villa","year":"2024","journal-title":"Brain Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Dai, C., Kang, J., Liu, X., Yao, Y., Wang, H., and Wang, R. (2021). How to Classify and Define Pituitary Tumors: Recent Advances and Current Controversies. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.604644"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Trouillas, J., Jaffrain-Rea, M.-L., Vasiljevic, A., Raverot, G., Roncaroli, F., and Villa, C. (2020). How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers, 12.","DOI":"10.3390\/cancers12020514"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO Classification of Pituitary Tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr. Pathol."},{"key":"ref_6","first-page":"e13302","article-title":"The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors","volume":"35","author":"Burman","year":"2024","journal-title":"Brain Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11154-025-09944-x","article-title":"Pituitary adenomas: Biology, nomenclature and clinical classification","volume":"26","author":"Ho","year":"2025","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.2174\/1871530321666210226152901","article-title":"From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways May Impact the Therapeutic Management?","volume":"21","author":"Chiloiro","year":"2021","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_9","first-page":"e13298","article-title":"Practical approaches to diagnosing PitNETs\/adenomas based on cell lineage","volume":"35","author":"Chacko","year":"2024","journal-title":"Brain Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s42000-020-00269-9","article-title":"Update on pituitary adenomas in the 2017 World Health Organization classification: Innovations and perspectives","volume":"20","author":"Kontogeorgos","year":"2021","journal-title":"Hormones"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s11596-022-2673-6","article-title":"Overview of the 2022 WHO Classification of Pituitary Adenomas\/Pituitary Neuroendocrine Tumors: Clinical Practices, Controversies, and Perspectives","volume":"42","author":"Wan","year":"2022","journal-title":"Curr. Med. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5603\/EP.a2020.0090","article-title":"Pituitary transcription factors in the immunohistochemical and molecular diagnosis of pituitary tumours\u2014A systematic review","volume":"72","author":"Burcea","year":"2021","journal-title":"Endokrynol. Pol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10014-021-00410-5","article-title":"Molecular, functional, and histopathological classification of the pituitary neuroendocrine neoplasms","volume":"38","author":"Inomoto","year":"2021","journal-title":"Brain Tumor Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/neuros\/nyaa548","article-title":"Neuropathology of Pituitary Adenomas and Sellar Lesions","volume":"88","author":"Kobalka","year":"2021","journal-title":"Neurosurgery"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10014-022-00441-6","article-title":"Aggressive nonfunctioning pituitary neuroendocrine tumors","volume":"39","author":"Portovedo","year":"2022","journal-title":"Brain Tumor Pathol."},{"key":"ref_16","first-page":"e220079","article-title":"The evolution in pituitary tumour classification: A clinical perspective","volume":"3","author":"Lenders","year":"2023","journal-title":"Endocr. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12022-021-09663-4","article-title":"Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?","volume":"32","author":"Asa","year":"2021","journal-title":"Endocr. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e13147","DOI":"10.1111\/jne.13147","article-title":"The corticotroph cells from early development to tumorigenesis","volume":"34","author":"Drouin","year":"2022","journal-title":"J. Neuroendocr."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hinojosa-Amaya, J.M., Lam-Chung, C.E., and Cuevas-Ramos, D. (2021). Recent Understanding and Future Directions of Recurrent Corticotroph Tumors. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.657382"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mouchtouris, N., Smit, R.D., Piper, K., Prashant, G., Evans, J.J., and Karsy, M. (2022). A review of multiomics platforms in pituitary adenoma pathogenesis. Front. Biosci., 27.","DOI":"10.31083\/j.fbl2703077"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Relav, L., Doghman-Bouguerra, M., Ruggiero, C., Muzzi, J.C.D., Figueiredo, B.C., and Lalli, E. (2023). Steroidogenic Factor 1, a Goldilocks Transcription Factor from Adrenocortical Organogenesis to Malignancy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043585"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/17446651.2022.2082942","article-title":"Recent advancements in the molecular biology of pituitary adenomas","volume":"17","author":"Zheng","year":"2022","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chang, M., Yang, C., Bao, X., and Wang, R. (2021). Genetic and Epigenetic Causes of Pituitary Adenomas. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.596554"},{"key":"ref_24","first-page":"112106","article-title":"Comparison of INSM1 immunostaining with established neuroendocrine markers synaptophysin and chromogranin A in over 14,000 neuroendocrine and non-neuroendocrine tumors","volume":"581","author":"Uhlig","year":"2023","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gheorghi\u0219an-G\u0103l\u0103\u021beanu, A.-A., Ilie\u0219iu, A., Lambrescu, I.M., and \u021a\u0103poi, D.A. (2023). The Complex Histopathological and Immunohistochemical Spectrum of Neuroendocrine Tumors\u2014An Overview of the Latest Classifications. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021418"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101894","DOI":"10.1016\/j.beem.2024.101894","article-title":"Histopathology of growth hormone-secreting pituitary tumors: State of the art and new perspectives","volume":"38","author":"Guaraldi","year":"2024","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s42000-021-00333-y","article-title":"High-risk pituitary adenomas and strategies for predicting response to treatment","volume":"21","author":"Kontogeorgos","year":"2022","journal-title":"Hormones"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Iglesias, P. (2025). Histopathological Types, Clinical Presentation, Imaging Studies, Treatment Strategies, and Prognosis of Posterior Pituitary Tumors: An Updated Review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14134553"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"152398","DOI":"10.1016\/j.anndiagpath.2024.152398","article-title":"PIT-1\/SF-1 co-expression in pituitary neuroendocrine tumors (PitNETs) with comprehensive review of the literature: How should we best characterize these neoplasms?","volume":"74","author":"Faraj","year":"2024","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"111726","DOI":"10.1016\/j.mce.2022.111726","article-title":"Synaptophysin and chromogranin A expression analysis in human tumors","volume":"555","author":"Uhlig","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic Classification of Pituitary Neuroendocrine Tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Serioli, S., Agostini, L., Pietrantoni, A., Valeri, F., Costanza, F., Chiloiro, S., Buffoli, B., Piazza, A., Poliani, P.L., and Peris-Celda, M. (2023). Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242115719"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S2213-8587(25)00227-X","article-title":"Prolactin-secreting adenomas: Pathogenesis, diagnosis, and management","volume":"13","author":"Fleseriu","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1530\/EO-22-0042","article-title":"Molecular mechanisms involved in somatostatin receptor regulation in corticotroph tumors: The role of cytoskeleton and USP8 mutations","volume":"2","author":"Peverelli","year":"2022","journal-title":"Endocr. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/cen.14472","article-title":"Towards precision medicine for clinically non-functioning pituitary tumours","volume":"95","author":"Lenders","year":"2021","journal-title":"Clin. Endocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12105-022-01435-8","article-title":"Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms","volume":"16","author":"Mete","year":"2022","journal-title":"Head Neck Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11102-023-01312-9","article-title":"Refractory Pit1 plurihormonal tumours and thyrotroph adenomas","volume":"26","author":"Nf","year":"2023","journal-title":"Pituitary"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2307\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:28:18Z","timestamp":1772688498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27052307"],"URL":"https:\/\/doi.org\/10.3390\/ijms27052307","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}